BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 29433514)

  • 1. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
    Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
    World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
    Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
    Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
    Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
    Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
    Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
    Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
    Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
    Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer.
    Mayanagi S; Tsubosa Y; Omae K; Niihara M; Uchida T; Tsushima T; Yokota T; Sato H; Naito T; Yasui H
    Ann Surg Oncol; 2017 Nov; 24(12):3741-3747. PubMed ID: 28861809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer.
    Nakashima Y; Saeki H; Hu Q; Tsuda Y; Zaitsu Y; Hisamatsu Y; Ando K; Kimura Y; Oki E; Mori M
    Ann Surg Oncol; 2020 Feb; 27(2):492-498. PubMed ID: 31549319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
    Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
    Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
    den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND
    BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?
    Saeki H; Nakashima Y; Kudou K; Sasaki S; Jogo T; Hirose K; Edahiro K; Korehisa S; Taniguchi D; Nakanishi R; Kubo N; Ando K; Kabashima A; Oki E; Maehara Y
    World J Surg; 2018 Sep; 42(9):2894-2901. PubMed ID: 29488065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
    Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
    Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of neoadjuvant chemotherapy on skeletal muscle depletion and preoperative sarcopenia in patients with resectable colorectal liver metastases.
    Eriksson S; Nilsson JH; Strandberg Holka P; Eberhard J; Keussen I; Sturesson C
    HPB (Oxford); 2017 Apr; 19(4):331-337. PubMed ID: 28089364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.
    Paireder M; Asari R; Kristo I; Rieder E; Tamandl D; Ba-Ssalamah A; Schoppmann SF
    Eur J Surg Oncol; 2017 Feb; 43(2):478-484. PubMed ID: 28024944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiopulmonary exercise testing has greater prognostic value than sarcopenia in oesophago-gastric cancer patients undergoing neoadjuvant therapy and surgical resection.
    West MA; Baker WC; Rahman S; Munro A; Jack S; Grocott MP; Underwood TJ; Levett DZ;
    J Surg Oncol; 2021 Dec; 124(8):1306-1316. PubMed ID: 34463378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
    Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer.
    Takahashi K; Watanabe M; Kozuki R; Toihata T; Okamura A; Imamura Y; Mine S; Ishizuka N
    Ann Surg Oncol; 2019 Oct; 26(11):3727-3735. PubMed ID: 31313039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
    Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
    Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of skeletal muscle measurement by computed tomography in patients with esophageal cancer: changes in skeletal muscle mass due to neoadjuvant therapy and the effect on the prognosis.
    Yamamoto M; Ozawa S; Koyanagi K; Kazuno A; Ninomiya Y; Yatabe K; Higuchi T; Kanamori K; Tajima K
    Surg Today; 2023 Jun; 53(6):692-701. PubMed ID: 36763134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
    Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
    Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.